Axogen shares rise 10.62% intraday after FDA approves AVANCE® acellular nerve allograft for peripheral nerve injury treatment in adults and children.

Axogen surged 10.62% intraday, with the company announcing that the U.S. FDA approved its AVANCE® acellular nerve allograft biologics license application on December 3, 2025. The product is indicated for treating peripheral nerve injuries in adults and children (aged one month and older), with some indications granted via accelerated approval. Axogen focuses on developing and marketing innovative surgical technologies to restore peripheral nerve function, with core products like AVANCE nerve grafts sold in the U.S., Canada, Germany, and other global markets.